secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099355
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track
--------------------------------------------------------------------------------

- Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
- Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.
- Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.
- Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.
- Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/0001193125-26-099355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer